ARTICLE | Discovery & Translation
Company’s first goals are to improve GLP-1s and CAR Ts with the ability to go from zero to very high expression, on demand
By Karen Tkach Tuzman, Director of Biopharma Intelligence
November 1, 2024 10:22 PM UTC
As MeiraGTx assembles its suite of technologies to control gene expression with oral pills, it has homed in on dynamic range as the element that will allow it to succeed where others have failed. Having built tailored, small molecule-activated riboswitches into its gene therapies, the company says it has achieved lower baselines and higher maximum expression than past attempts at gene control, opening the door to precision dosing of any biologic in vivo.
This preclinical platform is the last pillar of optimization in the clinical-stage company’s toolbox, according to CEO Alexandria (Zandy) Forbes. “There’s one major technology that has never been achieved, and that is to control gene expression with an oral pill,” she told BioCentury. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/653945/dynamic-range-the-key-to-meiragtx-s-quest-to-control-genes-with-pills